Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chikungunya vaccine shows promise for Long-Term protection

NCT ID NCT04838444

Vaccine Sponsor: Valneva Austria GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This Phase 3 trial follows adults who previously received the VLA1553 chikungunya vaccine to see how long their antibodies last and to monitor long-term safety. About 363 participants are being tracked for up to several years. The goal is to determine if a single shot can provide durable immunity against the virus.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VLA1553 (live-attenuated chikungunya virus vaccine)
What this could lead to
If successful, this could confirm that a single dose of the vaccine provides long-lasting protection against chikungunya.
What could go wrong
This is an open-label, single-arm study with no placebo group, so results may be less definitive. Long-term safety data are still being collected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

363 people

The number who actually took part.

Started

Apr 2021

Expected to finish

May 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individual participated in the VLA1553-301 clinical trial; * Participant has an understanding of the trial and its procedures, agrees to its provisions, and voluntarily gives written informed consent prior to any trial-related procedures; * Participant had immunogenicity blood samples taken at baseline (Visit 1) and either Day 29 (Visit 3), Day 85 (Visit 4) or Day 180 (Visit 5) in Trial VLA1553-301 and was negative for neutralizing antibodies at baseline Exclusion Criteria: * Participant presents with clinical conditions representing a contraindication to blood draws; * Participant has donated blood or use of blood products prior 30 days of immunogenicity sampling; * Participant has received an active drug with potential immunosuppressive action or investigational drug or device within a period of 30 days prior a trial visit; * Participant has a known or suspected problem with alcohol or drug abuse as determined by the Investigator; * Participant has any condition that, in the opinion of the Investigator, may compromise the participant's well-being, might interfere with evaluation of trial endpoints, or would limit the participant's ability to complete the trial; * Participant is committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities); * Participant is a member of the team conducting the trial or in a dependent relationship with one of the trial team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chikungunya virus infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chikungunya prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chikungunya virus infection

Contacts and locations

Locations

  • Accelerated Enrollment Solutions (AES)

    Phoenix, Arizona, 85020, United States

  • Accelerated Enrollment Solutions (AES)

    Chicago, Illinois, 60602, United States

  • Alliance for Multispecialty Research (AMR)

    Lexington, Kentucky, 40509, United States

  • Alliance for Multispecialty Research (AMR)

    Knoxville, Tennessee, 37920, United States

  • Allliance for Multispecialty Research (AMR)

    Norfolk, Virginia, 23502, United States

  • Velocity Clinical Research

    Hallandale, Florida, 33090, United States

  • Velocity Clinical Research

    Grand Island, Nebraska, 68803, United States

  • Velocity Clinical Research

    Omaha, Nebraska, 68134, United States

  • Velocity Clinical Research

    Austin, Texas, 78759, United States

  • Velocity Clinical Research

    West Jordan, Utah, 84088, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.